A share price of ProQR Therapeutics N.V [PRQR] is currently trading at $1.88, up 6.82%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PRQR shares have gain 4.44% over the last week, with a monthly amount drifted -2.08%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
ProQR Therapeutics N.V [NASDAQ: PRQR] stock has seen the most recent analyst activity on November 08, 2023, when Chardan Capital Markets upgraded its rating to a Buy but kept the price target unchanged to $2 for it. Previously, JMP Securities upgraded its rating to Mkt Outperform on March 30, 2023, and elevated its price target to $5. On December 22, 2022, upgrade upgraded it’s rating to Overweight and revised its price target to $5 on the stock. Citigroup downgraded its rating to a Neutral and decreased its price target to $1.70 on February 14, 2022. Stifel downgraded its rating to a Hold and reduced its price target to $3 on February 11, 2022. Raymond James downgraded its rating to Mkt Perform for this stock on February 11, 2022. In a note dated February 01, 2022, Raymond James initiated an Strong Buy rating and provided a target price of $19 on this stock.
ProQR Therapeutics N.V experienced fluctuations in its stock price throughout the past year between $1.11 and $3.29. Currently, Wall Street analysts expect the stock to reach $3.63 within the next 12 months. ProQR Therapeutics N.V [NASDAQ: PRQR] shares were valued at $1.88 at the most recent close of the market. An investor can expect a potential return of 93.09% based on the average PRQR price forecast.
Analyzing the PRQR fundamentals
Trailing Twelve Months sales for ProQR Therapeutics N.V [NASDAQ:PRQR] were 16.64M which represents 417.56% growth. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -1.85%, Pretax Profit Margin comes in at -1.39%, and Net Profit Margin reading is -1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.55 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7700 points at the first support level, and at 1.6600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9600, and for the 2nd resistance point, it is at 2.0400.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ProQR Therapeutics N.V [NASDAQ:PRQR] is 2.73. As well, the Quick Ratio is 2.73, while the Cash Ratio is 2.12. Considering the valuation of this stock, the price to sales ratio is 9.23, the price to book ratio is 4.36.
